CMSC Consensus Statement on Neurofilament Biomarkers in Multiple Sclerosis
Starts On:
Tue, 06/15/2021: 12:00 AM
Ends On:
Wed, 06/15/2022: 11:59 PM
Type:
Enduring Material
Credit Hours:
3
Session Description:
Release date: June 11, 2021
Valid through: June 30, 2022
Estimated Time to Complete Activity: 3 hours
Target Audience
This activity has been designed to meet the educational needs of physicians, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with multiple sclerosis (MS).
Faculty
Program Chairs
Mark Freedman, MD, MsC, FRCPC
University of Ottawa
Ottawa, Ontario, Canada
Sharmilee Gnanapavan, MD, PhD
Barts Health NHS Trust
London, England, UK
Writing Committee
Ronald Booth, PhD, DCC, FCAB
University Of Ottawa
Ottawa, Ontario, Canada
Peter Calabresi, MD
Johns Hopkins University
Baltimore, Maryland, USA
Michael Khalil, MD, PhD
Medical University of Graz
Graz, Austria
Jens Kuhle, MD, PhD
University Hospital Basel
Basel, Switzerland
David Leppert, MD
University Hospital Basel
Basel, Switzerland
Jan Lycke, MD, PhD
University of Gothenburg
Gothenburg, Sweden
Tomas Olsson, MD, PhD
Karolinska Institute
Solna, Sweden
Katherine Wandersee
Medical Writer, CMSC
Montclair, NJ
Advisory Panel
Bibiana Bielekova, MD
National Institutes of Health
Bethesda, Maryland, USA
Tanuja Chitnis, MD
Harvard Medical School
Boston, Massachusetts, USA
Manuel Comabella, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain
Robert Fox, MD
Cleveland Clinic
Cleveland, Ohio, USA
Roberto Furlan, MD, PhD
San Raffaele Scientific Institute
Milan, Italy
Gavin Giovannoni, MD, PhD
Barts and The London School of Medicine
London, England, UK
Joep Killestein, MD, PhD
Amsterdam University Medical Center
Amsterdam, The Netherlands
Sarah Morrow, MD, MS, FRCPC
Western University
London, Ontario, Canada
Daniel Ontaneda, MD, PhD
Cleveland Clinic
Cleveland, Ohio, USA
Michael Racke, MD
The Ohio State University
Columbus, Ohio, USA
Kottil Rammohan, MD
University of Miami
Miami, Florida, USA
Maria Pia Sormani, PhD
University of Genoa
Genoa, Italy
Simon Thebault, MD, MSc
University of Ottawa
Ottawa, Ontario, Canada
Valid through: June 30, 2022
Estimated Time to Complete Activity: 3 hours
Target Audience
This activity has been designed to meet the educational needs of physicians, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with multiple sclerosis (MS).
Faculty
Program Chairs
Mark Freedman, MD, MsC, FRCPC
University of Ottawa
Ottawa, Ontario, Canada
Sharmilee Gnanapavan, MD, PhD
Barts Health NHS Trust
London, England, UK
Writing Committee
Ronald Booth, PhD, DCC, FCAB
University Of Ottawa
Ottawa, Ontario, Canada
Peter Calabresi, MD
Johns Hopkins University
Baltimore, Maryland, USA
Michael Khalil, MD, PhD
Medical University of Graz
Graz, Austria
Jens Kuhle, MD, PhD
University Hospital Basel
Basel, Switzerland
David Leppert, MD
University Hospital Basel
Basel, Switzerland
Jan Lycke, MD, PhD
University of Gothenburg
Gothenburg, Sweden
Tomas Olsson, MD, PhD
Karolinska Institute
Solna, Sweden
Katherine Wandersee
Medical Writer, CMSC
Montclair, NJ
Advisory Panel
Bibiana Bielekova, MD
National Institutes of Health
Bethesda, Maryland, USA
Tanuja Chitnis, MD
Harvard Medical School
Boston, Massachusetts, USA
Manuel Comabella, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain
Robert Fox, MD
Cleveland Clinic
Cleveland, Ohio, USA
Roberto Furlan, MD, PhD
San Raffaele Scientific Institute
Milan, Italy
Gavin Giovannoni, MD, PhD
Barts and The London School of Medicine
London, England, UK
Joep Killestein, MD, PhD
Amsterdam University Medical Center
Amsterdam, The Netherlands
Sarah Morrow, MD, MS, FRCPC
Western University
London, Ontario, Canada
Daniel Ontaneda, MD, PhD
Cleveland Clinic
Cleveland, Ohio, USA
Michael Racke, MD
The Ohio State University
Columbus, Ohio, USA
Kottil Rammohan, MD
University of Miami
Miami, Florida, USA
Maria Pia Sormani, PhD
University of Genoa
Genoa, Italy
Simon Thebault, MD, MSc
University of Ottawa
Ottawa, Ontario, Canada
Learning Objectives:
Upon completing this activity, participants should be better able to:
Accreditation and Credit Designation
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Delaware Media Group require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Delaware Media Group mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Delaware Media Group seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Delaware Media Group are committed to providing learners with high-quality CE activities that promote improvements in health care and not a commercial interest
Physician Credit
The CMSC designates this journal-based activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Credit
The CMSC designates this enduring material for 3.0 contact hours (none in the area of pharmacology).
Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements, enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations, using procedures established by specific organizations.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Delaware Media Group require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Delaware Media Group mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Delaware Media Group seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Delaware Media Group are committed to providing learners with high-quality CE activities that promote improvements in health care and not a commercial interest.
Faculty Disclosures
The program faculty reported the following relevant financial relationships with ineligible companies:
Bibiana Bielekova, MD has disclosed no relevant financial relationships.
Ronald Booth, PhD, DCC, FCAB has disclosed no relevant financial relationships.
Peter Calabresi, MD has disclosed the following relevant financial relationships: Research Grants: Annexon Biogen; Scientific Advisory Board: Biogen, Disarm Therapeutics.
Tanuja Chitnis, MD has disclosed the following relevant financial relationships: Consultant: Biogen, Genentech, Novartis, Sanofi-Genzyme; Research Grants: Novartis Octave.
Manuel Comabella, MD, PhD has disclosed the following relevant financial relationships: Consultant: Biogen, Merck Serono, Roche, Sanofi, Teva Pharmaceuticals.
Robert Fox, MD has disclosed the following relevant financial relationships: Consultant: AB Science, Biogen, Celgene, EMD Serono, Genentech Genzyme, Immunic, Janssen, Novartis, Sanofi, TG Therapeutics
Mark Freedman, MD, MsC, FRCPC has disclosed the following relevant financial relationships: Consultant or Advisory Board: Actelion (Janssen, J&J), Alexion, Atara Biotherapeutics, Bayer Healthcare, Biogen, Celgene/BMS, Clene Nanomedicine, EMD Inc., GRI Bio, Magenta Therapeutics, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Teva Canada Innovation; Speaker's Bureau: EMD Serono, Sanofi-Genzyme; Research grants: EMD Inc. (Canada), Roche, Sanofi-Genzyme Canada.
Roberto Furlan, MD, PhD has disclosed the following relevant financial relationships: Consultant: Biogen, Genzyme, Merck, Novartis, Roche.
Gavin Giovannoni, MD, PhD has disclosed the following relevant financial relationships: Consultant: AbbVie, Janssen-Actelion, Atara Bio, Biogen, Celgene/BMS, EMD Serono, Genentech, GlaxoSmithKline, GW Pharma-Jazz Pharma, Japanese Tobacco, Merck, Novartis, Roche, Sanofi-Genzyme, Teva.
Sharmilee Gnanapavan, MD, PhD has disclosed the following relevant financial relationships: Consultant: Genzyme, Merck, Roche; Speaker's Bureau: TriMS, Neurodiem; Research grants: Genzyme, Merck, Takeda.
Michael Khalil, MD, PhD has disclosed the following relevant financial relationships: Scientific Advisory Board: Biogen, BMS, Gilead, Merck, Novartis, Roche; Speaker's Bureau: Biogen.
Joep Killestein, MD, PhD has disclosed the following relevant financial relationships: Research funding: Biogen, Genzyme, Merck, Novartis, Roche.
Jens Kuhle, MD, PhD has disclosed the following relevant financial relationships: Scientific Advisory Board or Research Support: Bayer, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, Sanofi
David Leppert, MD has disclosed the following relevant financial relationships: Chief Medical Officer, GeNeuro.
Jan Lycke, MD, PhD has disclosed the following relevant financial relationships: Advisory Board: Alexion, Allergan, Almiral, Celgene, Merck, Novartis, Roche, Sanofi; Research grants: Biogen, Novartis, Teva.
Sarah Morrow, MD, MS, FRCPC has disclosed no relevant financial relationships.
Tomas Olsson, MD, PhD has disclosed the following relevant financial relationships: Research Support: Biogen, Merck, Novartis, Roche, Sanofi
Daniel Ontaneda, MD, PhD has disclosed the following relevant financial relationships: Consultant: Biogen Idec, Genentech, Genzyme, Janssen, Novartis; Research grants: Genentech, Genzyme, Novartis.
Michael Racke, MD has disclosed the following relevant financial relationships: Consultant: Teva Neuroscience.
Kottil Rammohan, MD has disclosed the following relevant financial relationships: Consultant: Biogen, EMD Serono, Genentech, Genzyme, Novartis; Research grants: Biogen, EMD Serono, Genentech, Genzyme, Novartis.
Maria Pia Sormani, PhD has disclosed the following relevant financial relationships: Consultant: Biogen, GeNeuro, GlaxoSmithKline, Immunic Therapeutics, Merck, Novartis, Roche, Sanofi.
Simon Thebault, MD, MSc has disclosed no relevant financial relationships.
Katherine Wandersee has disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.
Staff Disclosures
The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have no relevant financial relationships with ineligible companies.
The planners, reviewers, editors, staff, or other members at Delaware Media Group who are in a position to control content have no relevant financial relationships with ineligible companies.
Media:
Print and Online
Method of Participation/How to Receive Credit
There is no fee to participate in this activity. To successfully complete this activity, the participant must
1) read the activity front matter, 2) complete the educational activity online, and 3) complete the post-test and activity evaluation.
To receive credit, participants must receive a minimum score of 60% (at least 5 out of 8 correct) on the post-test.
Disclosure of Unlabeled Use
CMSC and Delaware Media Group require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Commercial Support Acknowledgment
This activity is supported by educational grants received from Biogen and Sanofi Genzyme.
Disclaimer
CMSC and Delaware Media Group present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC, Delaware Media Group, and the commercial supporter(s) assume no liability for the information herein.
Privacy Policy
Copyright © 2021, Consortium of MS Centers and Delaware Media Group, Inc. All rights reserved. None of the contents of this supplement may be reproduced in any form without prior written permission. The opinions expressed in this program are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or the supporters
Contact Information
If you have any questions about this activity, please contact Delaware Media Group at jdonofrio@delmedgroup.com.
- Review techniques used to measure neurofilament biomarkers in serum and cerebrospinal fluid of patients with MS.
- Define neurofilament light chain (NfL) values and timing of NfL measurements and their clinical relevance in MS
- Discuss the influence of comorbid medical conditions on NfL outcomes
- Outline available strategies for applying NfL as a biomarker to aid in the clinical management of MS
Accreditation and Credit Designation
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Delaware Media Group require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Delaware Media Group mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Delaware Media Group seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Delaware Media Group are committed to providing learners with high-quality CE activities that promote improvements in health care and not a commercial interestPhysician Credit
The CMSC designates this journal-based activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Credit
The CMSC designates this enduring material for 3.0 contact hours (none in the area of pharmacology).
Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements, enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations, using procedures established by specific organizations.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Delaware Media Group require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Delaware Media Group mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Delaware Media Group seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Delaware Media Group are committed to providing learners with high-quality CE activities that promote improvements in health care and not a commercial interest.
Faculty Disclosures
The program faculty reported the following relevant financial relationships with ineligible companies:
Bibiana Bielekova, MD has disclosed no relevant financial relationships.
Ronald Booth, PhD, DCC, FCAB has disclosed no relevant financial relationships.
Peter Calabresi, MD has disclosed the following relevant financial relationships: Research Grants: Annexon Biogen; Scientific Advisory Board: Biogen, Disarm Therapeutics.
Tanuja Chitnis, MD has disclosed the following relevant financial relationships: Consultant: Biogen, Genentech, Novartis, Sanofi-Genzyme; Research Grants: Novartis Octave.
Manuel Comabella, MD, PhD has disclosed the following relevant financial relationships: Consultant: Biogen, Merck Serono, Roche, Sanofi, Teva Pharmaceuticals.
Robert Fox, MD has disclosed the following relevant financial relationships: Consultant: AB Science, Biogen, Celgene, EMD Serono, Genentech Genzyme, Immunic, Janssen, Novartis, Sanofi, TG Therapeutics
Mark Freedman, MD, MsC, FRCPC has disclosed the following relevant financial relationships: Consultant or Advisory Board: Actelion (Janssen, J&J), Alexion, Atara Biotherapeutics, Bayer Healthcare, Biogen, Celgene/BMS, Clene Nanomedicine, EMD Inc., GRI Bio, Magenta Therapeutics, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Teva Canada Innovation; Speaker's Bureau: EMD Serono, Sanofi-Genzyme; Research grants: EMD Inc. (Canada), Roche, Sanofi-Genzyme Canada.
Roberto Furlan, MD, PhD has disclosed the following relevant financial relationships: Consultant: Biogen, Genzyme, Merck, Novartis, Roche.
Gavin Giovannoni, MD, PhD has disclosed the following relevant financial relationships: Consultant: AbbVie, Janssen-Actelion, Atara Bio, Biogen, Celgene/BMS, EMD Serono, Genentech, GlaxoSmithKline, GW Pharma-Jazz Pharma, Japanese Tobacco, Merck, Novartis, Roche, Sanofi-Genzyme, Teva.
Sharmilee Gnanapavan, MD, PhD has disclosed the following relevant financial relationships: Consultant: Genzyme, Merck, Roche; Speaker's Bureau: TriMS, Neurodiem; Research grants: Genzyme, Merck, Takeda.
Michael Khalil, MD, PhD has disclosed the following relevant financial relationships: Scientific Advisory Board: Biogen, BMS, Gilead, Merck, Novartis, Roche; Speaker's Bureau: Biogen.
Joep Killestein, MD, PhD has disclosed the following relevant financial relationships: Research funding: Biogen, Genzyme, Merck, Novartis, Roche.
Jens Kuhle, MD, PhD has disclosed the following relevant financial relationships: Scientific Advisory Board or Research Support: Bayer, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, Sanofi
David Leppert, MD has disclosed the following relevant financial relationships: Chief Medical Officer, GeNeuro.
Jan Lycke, MD, PhD has disclosed the following relevant financial relationships: Advisory Board: Alexion, Allergan, Almiral, Celgene, Merck, Novartis, Roche, Sanofi; Research grants: Biogen, Novartis, Teva.
Sarah Morrow, MD, MS, FRCPC has disclosed no relevant financial relationships.
Tomas Olsson, MD, PhD has disclosed the following relevant financial relationships: Research Support: Biogen, Merck, Novartis, Roche, Sanofi
Daniel Ontaneda, MD, PhD has disclosed the following relevant financial relationships: Consultant: Biogen Idec, Genentech, Genzyme, Janssen, Novartis; Research grants: Genentech, Genzyme, Novartis.
Michael Racke, MD has disclosed the following relevant financial relationships: Consultant: Teva Neuroscience.
Kottil Rammohan, MD has disclosed the following relevant financial relationships: Consultant: Biogen, EMD Serono, Genentech, Genzyme, Novartis; Research grants: Biogen, EMD Serono, Genentech, Genzyme, Novartis.
Maria Pia Sormani, PhD has disclosed the following relevant financial relationships: Consultant: Biogen, GeNeuro, GlaxoSmithKline, Immunic Therapeutics, Merck, Novartis, Roche, Sanofi.
Simon Thebault, MD, MSc has disclosed no relevant financial relationships.
Katherine Wandersee has disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.
Staff Disclosures
The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have no relevant financial relationships with ineligible companies.
The planners, reviewers, editors, staff, or other members at Delaware Media Group who are in a position to control content have no relevant financial relationships with ineligible companies.
Media:
Print and Online
Method of Participation/How to Receive Credit
There is no fee to participate in this activity. To successfully complete this activity, the participant must
1) read the activity front matter, 2) complete the educational activity online, and 3) complete the post-test and activity evaluation.
To receive credit, participants must receive a minimum score of 60% (at least 5 out of 8 correct) on the post-test.
Disclosure of Unlabeled Use
CMSC and Delaware Media Group require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Commercial Support Acknowledgment
This activity is supported by educational grants received from Biogen and Sanofi Genzyme.
Disclaimer
CMSC and Delaware Media Group present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC, Delaware Media Group, and the commercial supporter(s) assume no liability for the information herein.
Privacy Policy
Copyright © 2021, Consortium of MS Centers and Delaware Media Group, Inc. All rights reserved. None of the contents of this supplement may be reproduced in any form without prior written permission. The opinions expressed in this program are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or the supporters
Contact Information
If you have any questions about this activity, please contact Delaware Media Group at jdonofrio@delmedgroup.com.
Credit Types
CME: 3.00
Letter of Completion: 3.00
NCPD: 3.00
